POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

Vaccine for Wuhan coronavirus may be ready in 3 months

Christian Fernsby |
U.S. health scientists said in an essay yesterday that a candidate vaccine for Wuhan novel coronavirus could be ready for early stage human testing in three months.

Article continues below



Topics: VACCINE    WUHAN    CORONAVIRUS   

In an essay published on the U.S. medical journal JAMA, Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, and Catharine Paules, an assistant professor of infectious diseases at Penn State University, said advances in technology since the SARS outbreak in 2003 have greatly compressed the vaccine development timeline.

The researchers moved from obtaining the genomic sequence of SARS virus to a phase one clinical trial of a DNA vaccine in 20 months and have since compressed that timeline to 3.25 months for other viral diseases.

The scientists hope to move even faster for 2019-nCoV, using messenger RNA (mRNA) vaccine technology, according to the authors.

The predominant human receptor for the SARS glycoprotein is human angiotensin-converting enzyme 2 (ACE2). Preliminary analyses indicated that 2019-nCoV has some amino acid homology to SARS virus and may be able to use ACE2 as a receptor.

This could have important implications for predicting pandemic potential moving forward, said the authors.

Also, the emergence of yet another outbreak of human disease caused by a pathogen from a viral family formerly thought to be relatively benign underscores the perpetual challenge of emerging infectious diseases and the importance of sustained preparedness, the authors said.

U.S. and Chinese medical institutions are working together to develop a vaccine against the novel coronavirus which has already caused 830 confirmed cases of pneumonia in China as of Thursday.

The World Health Organization (WHO) said yesterday that it was "too early" to declare the outbreak of the novel coronavirus in China a public health emergency of international concern, while warning that the number of cases may rise as many about the virus remain unknown.


What to read next

CDC: First case of Wuhan coronavirus confirmed in U.S.
DNA-based vaccine guards against Zika in monkey study
Japan confirms Wuhan virus